Symbiotec Pharmalab IPO subscription crossed 5.5 times on August 27, the final day of bidding, reflecting strong demand for the pharmaceutical CDMO company’s ₹1,757 crore public issue. The IPO closes Thursday, with investors closely tracking category-wise demand and the company’s upcoming listing.
Symbiotec Pharmalab IPO sees strong final-day demand
The Symbiotec Pharmalab IPO attracted strong investor interest on its final day of bidding, with the issue subscribed more than 5.5 times by 10:10 am on August 27, according to NSE data reported by Moneycontrol. The public issue opened on August 24 and is scheduled to close at 5 pm on August 27.
Symbiotec Pharmalab, a Madhya Pradesh-based pharmaceutical and biotechnology company, is raising ₹1,757 crore through the mainboard IPO. The issue has a price band of ₹938 to ₹988 per equity share, with a lot size of 15 shares. At the upper price band, retail investors need ₹14,820 for one lot.
The final subscription figure can change during the remaining hours of bidding. Investors are therefore watching the closing-day numbers, particularly demand from qualified institutional buyers and non-institutional investors.
₹1,757 crore IPO includes fresh issue and OFS
The Symbiotec Pharmalab IPO comprises a ₹150 crore fresh issue and an offer for sale worth about ₹1,607 crore. This means the majority of the issue proceeds will go to existing shareholders selling their holdings rather than directly into the company’s balance sheet.
The company has stated that proceeds from the fresh issue will be used primarily for repayment or prepayment of certain outstanding borrowings and for general corporate purposes. The offer for sale component, meanwhile, allows existing shareholders to monetise part of their investment.
The distinction is important for investors because a fresh issue can provide new capital to the business, while an OFS generally transfers ownership from selling shareholders to public investors without adding the same amount of capital to the company.
Symbiotec Pharmalab focuses on specialised APIs
Symbiotec Pharmalab operates across pharmaceuticals and biotechnology, with capabilities spanning organic chemistry, biotechnology and complex injectables. The company has a particular presence in active pharmaceutical ingredients, including corticosteroid and steroidal-hormone APIs.
Its business has a substantial international component. More than two-thirds of its revenue comes from global markets, with Europe accounting for around 30% of revenue, according to an Economic Times analysis of the IPO.
The company has also commissioned a 400 kilolitre biomanufacturing facility at its Ujjain facility. Its specialised manufacturing capabilities are a key part of the investment case being considered by IPO investors.
The company reported total income of ₹872.26 crore in FY26, compared with ₹723.34 crore in FY24. Profit after tax increased from ₹100.06 crore in FY24 to ₹109.90 crore in FY26.
Investor demand builds despite valuation concerns
Strong subscription does not necessarily mean that the IPO is free from valuation or business risks.
At the upper price band of ₹988, Symbiotec Pharmalab’s valuation has drawn attention because of its earnings multiple. An Economic Times analysis highlighted the company’s specialised product portfolio and valuation relative to industry peers, while also noting risks associated with product concentration and international exposure.
The company’s top five products account for approximately 63% of revenue, according to the same analysis. Such concentration can create additional business risk if demand for a major product changes or if competitive, regulatory or pricing conditions shift.
The company’s overseas exposure also means that currency movements, international regulations and geopolitical developments can influence financial performance.
Grey market premium adds to IPO buzz
The Symbiotec Pharmalab IPO has also generated considerable attention in the unofficial grey market.
Moneycontrol reported a grey market premium of around ₹285 per share on August 27, equivalent to approximately 29% above the IPO’s upper price band.
Grey market premium figures are not official exchange data and should not be treated as a guaranteed indicator of the eventual listing price. The actual listing will depend on market conditions, investor demand, company fundamentals and broader sentiment at the time of listing.
The IPO is scheduled to be listed on September 1, according to current IPO timelines. Allotment is expected to be finalised after the issue closes.
Anchor investors had already committed ₹526 crore
Before the IPO opened, Symbiotec Pharmalab received strong institutional backing through its anchor book.
The company raised ₹526.20 crore from anchor investors ahead of the public issue. The anchor allocation included institutional names such as Citi Group and Singularity, according to Economic Times.
Anchor participation can provide an indication of institutional interest before retail and other public investors begin bidding. However, it does not eliminate the normal risks associated with an IPO or guarantee post-listing performance.
The public issue subsequently attracted substantial demand across investor categories as the subscription period progressed.
What investors are watching before the IPO closes
The key focus for investors on August 27 is the final subscription figure and the category-wise response.
Earlier subscription data showed strong participation from retail and non-institutional investors, while qualified institutional buyer participation had been comparatively slower during the initial stages. By the final day, the overall subscription had moved above 5.5 times by 10:10 am.
Investors are also assessing the company’s earnings growth, international revenue exposure, specialised API portfolio and planned use of fresh IPO proceeds.
At the same time, product concentration, working-capital requirements, dependence on global markets and the large offer-for-sale component remain important considerations.
The final subscription number will provide a clearer picture of demand once bidding closes, but it will not by itself determine how the stock performs after listing.
IPO closes today as listing date approaches
The Symbiotec Pharmalab IPO closes on August 27, bringing the four-day bidding process to an end. The issue has drawn attention because of its ₹1,757 crore size, specialised pharmaceutical manufacturing business and strong subscription momentum on the final day.
The next major milestones will be the basis of allotment and the company’s stock-market debut. Current IPO schedules indicate allotment finalisation on August 28 and listing on September 1.
For investors, the stronger subscription figure signals demand, but the longer-term performance of the stock will depend on Symbiotec Pharmalab’s ability to grow earnings, manage its specialised manufacturing operations and maintain demand across its domestic and international markets.
Key takeaways
- Symbiotec Pharmalab IPO was subscribed more than 5.5 times by 10:10 am on August 27, its final bidding day.
- The ₹1,757 crore IPO has a price band of ₹938 to ₹988 per share and a lot size of 15 shares.
- The issue includes ₹150 crore of fresh shares and around ₹1,607 crore through an offer for sale.
- The company is scheduled to complete allotment formalities before a planned September 1 listing.
FAQ
How much is the Symbiotec Pharmalab IPO subscribed?
The IPO was subscribed more than 5.5 times by 10:10 am on August 27, according to NSE data cited by Moneycontrol. The final subscription figure can change until bidding closes.
What is the price band of the Symbiotec Pharmalab IPO?
The IPO has a price band of ₹938 to ₹988 per equity share. The lot size is 15 shares, making ₹14,820 the minimum investment at the upper price band for one retail lot.
How large is the Symbiotec Pharmalab IPO?
The public issue is worth ₹1,757 crore. It includes a ₹150 crore fresh issue and an offer for sale of approximately ₹1,607 crore.
When will Symbiotec Pharmalab shares list?
Current IPO schedules indicate that the shares are expected to list on September 1, 2026, following the allotment process.
(Internal keywords: Symbiotec Pharmalab IPO, Symbiotec Pharmalab IPO subscription, Symbiotec IPO latest news, Symbiotec Pharmalab IPO GMP, Symbiotec IPO price band, ₹1,757 crore IPO, Symbiotec IPO allotment, Symbiotec Pharmalab listing date, pharmaceutical IPO India, mainboard IPO August 2026)
